Centriair enters into a partnership with Recul AS to further strengthen its position in odor control for wastewater and waste management applications in the Norwegian market.
We look forward to a strong collaboration with the Norwegian odor specialist company Recul, with Siv Malmanger and Jon Stiansen, who will represent Centriair as resellers in the Norwegian market.
Recul holds a unique position in the Norwegian market with a leading role in odor reduction, and together with Centriair’s unique product portfolio and solutions, they will be able to offer customers a broader range of solutions and further market coverage.
Odour is a significant challenge in sectors such as waste management, food processing, biogas production, slaughterhouses, rendering plants, and wastewater treatment. These industries generate strong and persistent odours. If not properly managed, these odours can affect employees, nearby communities, and the overall perception of the industry,
Efficient air purification is essential in frying applications to ensure a clean and sustainable production process. By combining centrifugal particle separation with ColdOx™ technology, both particulate matter and odorous VOC emissions can be effectively removed. This not only improves air quality but also enables heat recovery, reduces maintenance, and lowers energy consumption. Discover how our integrated solution enhances efficiency, minimizes operational costs, and ensures compliance with strict environmental regulations.
Odour, or stench, generated in industrial processes is the result of chemical reactions and biological processes that release odour-generating substances and gases. These may include aldehydes, terpenes, sulfur-containing compounds, amines, volatile organic compounds (VOCs), and other gaseous substances. The intensity and character of the odour depend on the chemical structure of these substances and their odour threshold, which is the lowest concentration at which humans can perceive the scent.
Banbrytande kunskap om luktsystemet togs fram utav Richard Axel och Linda Buck, i en ventenskaplig publikation från 1991. Deras forskning tilldelades Nobelpriset I Medicin 2004. Mer information på Nobelstiftelsens hemsida (bilder från Nobelstiftelsen inlänkade nedan).